Posters & Publications

| Posters | Archives |

June 2018
ASCO: A phase I pharmacokinetic and pharmacodynamic study of PLX9486 alone and in combination with the KIT inhibitors pexidartinib (pexi) or sunitinib in patients with advanced solid tumors and gastrointestinal stromal tumor (GIST)
November 2017
CTOS: A Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of PLX9486, A Novel KIT Inhibitor with Potent Activity Against Exon 17/18 Activation Loop Mutations in Patients with Gastrointestinal Stromal Tumor (GIST)
More information is coming soon.